Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis Gaillard et al. EquipeELC 2021-10-21
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients Jacquet et al. EquipeCTCS May 2018
5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study Ploquin et al. EquipeELC 05 2018
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study Delaloge et al. EquipeCTCS 09/2016
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial Blanchard et al. EquipeCG Sep 25 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Fizazi et al. EquipeCG May 28 2015
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France Houede et al. EquipeCG 2015
A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer Houede et al. EquipeCG Dec 2014


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés